Benchmark Research

Austin, Texas 78728

0 studies enrolling now · 60 studies all time

What they study most

Acute Gastroenteritis, COVID-19, Clostridium Difficile Associated Disease, Clostridoides Difficile Associated Disease, Cytomegalovirus, Ebola Sudan Virus Disease, Epstein-Barr Virus Infection, Genital Herpes, Healthy Participants, Healthy or Stable Underlying Chronic Medical Condition, Herpes Labialis, Hot Flashes

Studies at this site

• A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis — Running, not enrolling
• Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children — Completed
• A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 — Completed
• To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults — Running, not enrolling
• Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults — Completed
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals — Completed
• A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza — Completed
• A Study of Modified mRNA Vaccines in Healthy Adults — Completed
• Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. — Running, not enrolling
• A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults — Completed
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. — Completed
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. — Completed
• A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals — Completed
• Effect of KYG0395 on Primary Dysmenorrhea — Completed
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants — Running, not enrolling
• A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 — Completed
• A Strain Change Study for SARS-CoV-2 rS Vaccines — Completed
• Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines — Completed
• Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines — Completed
• A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older — Completed
• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants — Completed
• Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health — Completed
• Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults — Completed
• A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. — Completed
• A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old — Completed
• Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age — Completed
• A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. — Completed
• Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age — Completed
• Use of Wearable Digital Sensors After mRNA Vaccination in Adults — Completed
• Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine — Completed
• Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age — Completed
• Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older — Completed
• A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults — Completed
• Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 — Completed
• Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age — Completed
• Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults — Running, not enrolling
• A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults — Completed
• A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years — Completed
• A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS — Completed
• Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults — Completed
• Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults — Completed
• Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age — Completed
• A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation — Completed
• Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years — Completed
• Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years — Completed
• A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17 — Completed
• A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat — Completed
• A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine. — Completed
• Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults. — Completed
• A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years — Completed